Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead Gets OK for Delivery Technology Patent

Premium

Arrowhead Research this week announced that it has received notice from the US Patent and Trademark Office that it will be issued a patent on its dynamic polyconjugate siRNA delivery technology.

Dynamic polyconjugates, or DPCs, are nanoparticles composed of an amphipathic polymer to which shielding agents such as polyethylene glycol, as well as targeting ligands, are reversibly attached, according to Arrowhead. The company acquired the technology when it bought Roche's RNA drug assets last year (GSN 10/27/2011).

According to Arrowhead, the USPTO said it will grant a patent on an application entitled “Compositions for Targeted Delivery of siRNA,” which covers compositions, methods, and uses for a new formulation of the DPCs.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.